Stay updated with breaking news from Superkine Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
— Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights Medicenna Therapeutics Corp.February 12, 2021 GMT TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended December 31, 2020. All dollar amounts are expressed in Canadian currency unless otherwise ...